289717-57-3

Basic information

• Product Name: 1-[2-(4-CHLOROPHENOXY)-5-FLUOROPHENYL]-N-METHYLMETHYLAMINE
• Synonyms: [2-(4-CHLORO-PHENOXY)-5-FLUORO-BENZYL]-METHYL-AMINE;1-[2-(4-CHLOROPHENOXY)-5-FLUOROPHENYL]-N-METHYLMETHYLAMINE;2-(4-Chlorophenoxy)-5-fluoro-N-methylbenzylamine
• CAS NO: 289717-57-3
• Molecular Formula: C14H13ClFNO
• Molecular Weight: 265.71
• Mol File: 289717-57-3.mol

Chemical Properties

• Boiling Point: 323.257°C at 760 mmHg
• Flash Point: 149.301°C
• Appearance: /
• Density: 1.22g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.563
• CAS DataBase Reference: 1-[2-(4-CHLOROPHENOXY)-5-FLUOROPHENYL]-N-METHYLMETHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[2-(4-CHLOROPHENOXY)-5-FLUOROPHENYL]-N-METHYLMETHYLAMINE(289717-57-3)
• EPA Substance Registry System: 1-[2-(4-CHLOROPHENOXY)-5-FLUOROPHENYL]-N-METHYLMETHYLAMINE(289717-57-3)

Safety Data

• Hazardous Substances Data: 289717-57-3(Hazardous Substances Data)

Usage

Chemical class

Substituted anilines

Molecular weight

276.7 g/mol

Usage

Intermediate in the synthesis of pharmaceuticals and agricultural chemicals

Usage

Research and development laboratories for various applications

Chemical structure

Substituted aniline group with a chlorine atom and a fluorine atom attached to a phenyl ring

Additional functional group

N-methylmethylamine group

InChI:InChI=1/C14H13ClFNO/c1-17-9-10-8-12(16)4-7-14(10)18-13-5-2-11(15)3-6-13/h2-8,17H,9H2,1H3

Relevant articles and documents

Monoamine reuptake inhibitors for treatment of CNS disorders

The present invention relates to compounds of the formula wherein R1through R4, X, Y, m and n are defined as in the specification. Such compounds are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibito

Combination treatment for alcoholism and alcohol dependence

The present invention relates to a method of treating alcoholism or alcohol dependence in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with an opioid antagonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and an opioid antagonist.

Combination treatment for anxiety and depression

The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a GABA-A alpha ? agonist in combination with an SRI antidepressant agent with improvement in efficacy. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a GABA-A alpha ? agonist, and an SRI antidepressant agent.

Combination treatment for depression

The present invention relates to a method of treating depression, especially refractory depression, in a mammal, including a human, by administering to the mammal a sigma receptor ligand in combination with an antidepressant agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a sigma receptor ligand and a serotonin reuptake inhibitor.

Monoamine reuptake inhibitors for treatment of CNS disorders

The present invention relates to compounds of the formula wherein R1 through R4, X, Y, m and n are defined as in the specification. Such compounds are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibit

Combination treatment for depression

The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a 5-HT3 receptor antagonist in combination with an SRI antidepressant agent with improvement in sexual function and/or reduction in gastro-intestinal side effects. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5-HT3 receptor antagonist and an SRI antidepressant.

Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis

The present invention relates to a method of treating depression, obsessive compulsive disorder and psychosis in a mammal, including a human, by administering to the mammal an atypical antipsychotic in combination with an antidepressant agent with improvement in efficiency. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, an atypical antipsychotic, and an SRI.

Combination treatment for sleep disorders including sleep apnea

The present invention relates to a method of treating sleep disorders including sleep apnea in a mammal, including a human, by administering to the mammal a 5HT1a antagonist or an alpha-2-adrenergic antagonist in combination with an SRI antidepressant agent with improvement in efficacy. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5HT1a antagonist or an alpha-2-adrenergic antagonist, and an SRI antidepressant agent.

Combination treatment for depression and anxiety

The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with a dopamine D3 receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and a dopamine D3 receptor agonist.